Skip to main content
Neeta Somaiah, MD, Oncology, Houston, TX

NeetaSomaiahMD

Oncology Houston, TX

Physician

Dr. Somaiah is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Somaiah's full profile

Already have an account?

  • Office

    1515 Holcombe Blvd
    Houston, TX 77030
    Phone+1 713-792-8850
    Fax+1 843-792-0644

Education & Training

  • Temple University Hospital-Fox Chase Cancer Center
    Temple University Hospital-Fox Chase Cancer CenterFellowship, Hematology and Medical Oncology, 2006 - 2009
  • St John's Episcopal Hospital-South Shore
    St John's Episcopal Hospital-South ShoreInternship, Internal Medicine, 2002 - 2003
  • Maulana Azad Medical College
    Maulana Azad Medical CollegeClass of 2001

Certifications & Licensure

  • FL State Medical License
    FL State Medical License 2021 - Present
  • AZ State Medical License
    AZ State Medical License 2023 - 2026
  • TX State Medical License
    TX State Medical License 2012 - 2026
  • MS State Medical License
    MS State Medical License 2023 - 2025
  • OK State Medical License
    OK State Medical License 2020 - 2025
  • TN State Medical License
    TN State Medical License 2023 - 2025
  • WA State Medical License
    WA State Medical License 2023 - 2025
  • American Board of Internal Medicine Medical Oncology
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Journal Articles

  • Characteristics and Outcomes of Patients with Advanced Sarcoma Enrolled in Early Phase Immunotherapy Trials  
    David S Hong, Neeta Somaiah, Anthony Conley, Shreyaskumar Patel, Filip Janku, Aung Naing, Kenneth Hess, Robert Benjamin, BioMed Central

Lectures

  • Phase II trial of gemcitabine (G) with pazopanib (P) or gemcitabine with docetaxel (T) in advanced soft tissue sarcoma (STS). 
    ASCO Annual Meeting 2019 - Chicago, IL - 6/3/2019

Press Mentions

  • Clinical Trial Results Support Uninterrupted Use of Imatinib for Some Gastrointestinal Stromal Tumors
    Clinical Trial Results Support Uninterrupted Use of Imatinib for Some Gastrointestinal Stromal TumorsSeptember 19th, 2024
  • Myxoid Liposarcoma: Diagnosis, Treatment and Prognosis
    Myxoid Liposarcoma: Diagnosis, Treatment and PrognosisSeptember 5th, 2024
  • Strong Support for Not Interrupting Imatinib Treatment in Advanced GIST
    Strong Support for Not Interrupting Imatinib Treatment in Advanced GISTAugust 20th, 2024
  • Join now to see all

Professional Memberships